On January 4, 2018 Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers reported that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 9:30 AM PT (12:30 PM ET) at the Westin St. Francis Hotel in San Francisco, CA (Press release, Stemline Therapeutics, JAN 4, 2018, View Source [SID1234522874]). A live webcast of the presentation can be viewed on the company’s website at www.stemline.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 4, 2018 AVEO Oncology (NASDAQ:AVEO) reported that Michael Bailey, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 11:30 a.m. Pacific Time (Press release, AVEO, JAN 4, 2018, View Source;p=RssLanding&cat=news&id=2324826 [SID1234522876]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

On January 4, 2018 Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, reported that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 9:00 a.m. Pacific time (Press release, Ignyta, JAN 4, 2018, View Source [SID1234522878]). The conference will be held at the Westin St. Francis Hotel in San Francisco.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available during the presentation in the Investors section of the company’s website at View Source, and will be archived and available at that site for 14 days.

On January 4, 2018 ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, reported that Pieter Rottiers, PhD, ActoBio’s Chief Executive Officer, will present at the Biotech Showcase 2018 Conference in San Francisco on Monday, January 8th at 2 p.m. Pacific Time (Press release, Intrexon, JAN 4, 2018, View Source [SID1234522881]). The presentation will highlight the innovative, proprietary ActoBiotics drug delivery platform for oral and topical administration of biologicals to address unmet medical needs for diverse health indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ActoBio Therapeutics combines world-class science, preclinical and clinical-stage products, and a leadership team with over 20 years hands-on experience developing the platform. ActoBio has reached a significant level of development and is well prepared to move forward to create significant new therapeutic modalities across a broad set of markets with strong growth dynamics including oral, gastrointestinal, and autoimmune/allergic disorders. Using the innovative ActoBiotics platform, we have built a strong R&D pipeline with the latest stage therapeutic candidate in Phase 2b and an extensive portfolio of candidates both partnered and self-owned ready for clinical development across a number of conditions," Dr. Rottiers commented.

A live webcast of the presentation will be available on the Investors section of Intrexon’s website at View Source Replay of the webcast will be available for 30 days following the event.

On January 4, 2018 Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, reported that Randal J. Kirk, Chairman and Chief Executive Officer will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10th at 9:30 a.m. Pacific Time (Press release, Intrexon, JAN 4, 2018, View Source [SID1234522882]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors section of Intrexon’s website at View Source Replay of the webcast will be available for 30 days following the event.